Pharmacokinetic Individualisation of Zidovudine Therapy: Current State of Pharmacokinetic-Pharmacodynamic Relationships

Clinical Pharmacokinetics

Volumn 30, Issue 4, 1996, Pages 314-327

  Hoetelmans, Richard M W ^a   Burger, David M ^b   Meenhorst, Pieter L ^a   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

BONE MARROW SUPPRESSION; DRUG MECHANISM; DRUG MONITORING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; HIV INFECTIONS; PRODRUGS; ZIDOVUDINE;

EID: 0029990212     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630040-00004     Document Type: Article

References (98)

1. Horwitz JP, Chua J, Noel M. Nucleosides. V: The monumesylates of 1-(2′-deoxy-beta-D-lyxofuranosyl) thymidine. J Org Chem 1964; 29: 2076-8
2. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100
3. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993; 328: 1686-95
4. Portegies P, De Gans J, Lange JMA, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989; 299: 819-21
5. Schmitt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988; 319: 1573-8
6. Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1989; 37: 408-50
7. Kong X-B, Zhu Q-Y, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992; 36: 808-18
8. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-7
9. Oates JA, Wood AJJ. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989; 321: 726-38
10. Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989; 264: 6127-33
11. Balzarini J, Pauwels R, Baba M, et al. The in vitro and in vivo anti-retrovirus activity and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988; 37: 897-903
12. Cheng YC, Dutschman GE, Bastow KF, et al. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem 1987; 262: 2187-9
13. St. Clair MH, Richards CA, Spector T, et al. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987; 31: 1972-7
14. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; I (8481): 575-80
15. Huang P, Farquhar D, Plunkett W. Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 1990; 265: 11914-8
16. Mitsuya H, Jarrett RF, Matsukura M, et al. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proc Natl Acad Sci USA 1987; 84: 2033-7
17. Toji L, Cohen SS. The enzymatic termination of polydeoxynucleotides by 2′,3′-dideoxyadenosine triphosphate. Proc Natl Acad Sci USA 1969; 63: 871-7
18. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7
19. Tan CK, Civil R, Mian AM, et al. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry 1991; 30: 4831-5
20. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990; 249: 1533-44
21. Waqar MA, Evans MJ, Manly KF. Effects of 2′,3′-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol 1984; 121: 402-8
22. Harrington JA, Reardon JE, Spector T. 3′-Azido-3′-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA. Antimicrob Agents Chemother 1993; 37: 918-20
23. Sommadossi J-P, Carlisle R, Zhou Z. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 1989; 36: 9-14
24. Tosi P, Calabresi P, Goulette FA, et al. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res 1992; 52: 4069-73
25. Vazquez-Padua MA, Starnes MC, Cheng Y-C. Incorporation of 3′-azido-3′- deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun 1990; 2: 55-62
26. Toyoshima T, Kimura S, Muramatsu S, et al. A sensitive non-isotopic method for the determination of intracellular azidothymidine 5′-mono-, 5′-di-, and 5′-triphosphate. Anal Biochem 1991; 196: 302-7
27. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8: F1-5
28. Cretton EM, Xie M-Y, Bevan RJ, et al. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine. a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1991; 42: 1475-80
29. Avramis VI, Markson W, Jackson RL, et al. Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS 1989; 3: 417-22
30. Frick LW, Nelson DJ, St Clair MH, et al. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun 1988; 154: 124-9
31. Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 46: 515-78
32. Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993; 24: 101-23
33. Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine: an overview of current data. Clin Pharmacokinet 1989; 17: 1-9
34. Burger DM, Meenhorst PL, Beijnen JH. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents. Pharm World Sci 1995; 17: 25-30
35. Acosta EP, Page LM, Fletcher VF. Clinical pharamacokinetics of zidovudine: an update. Clin Pharmacokinet 1996 Apr; 30 (4): 251-262
36. Burger DM, Meenhorst PL, ten Napel CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 1994; 8: 1683-9
37. Blum RM, Liao SHT, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85 Suppl. 2A: 189-94
38. Cload PA. A review of the pharmacokinetics of zidovudine in man. J Infect 1989; 18 Suppl. 1: 15-21
39. Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407-12
40. Macnab KA, Gill MJ, Sutherland LR, et al. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother 1993; 31: 421-8
41. Zorza G, Beaugerie L, Taburet A-M, et al. Absorption of zidovudine in patients with diarrhoea. Eur J Clin Pharmacol 1993; 44: 501-3
42. Drew RH, Weller S, Gallis HA, et al. Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1989; 33: 1801-3
43. Unadkat JD, Collier AC, Crosby SS, et al. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 1990; 4: 229-32
44. Lotterer E, Ruhnke M, Trautmann M, et al. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 1991; 40: 305-8
45. Sahai J, Gallicano K, Garber G, et al. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol 1992; 33: 657-60
46. Ruhnke M, Bauer FE, Seifert M, et al. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2153-8
47. Shelton MJ, Portmore A, Blum R, et al. Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy 1994; 14: 671-7
48. Gitterman SR, Drusano GL, Egorin MJ, et al. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990; 48: 161-7
49. Rolinski B, Wintergerst U, Matuschke A, et al. Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS 1991; 5: 885-8
50. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581-7
51. Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992; 33: 190-2
52. Kuster H, Vogt M, Joos B, et al. A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis 1991; 164: 773-6
53. Slusher JT, Kuwahara SK, Hamzeh FM, et al. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 1992; 36: 2473-7
54. Avramis VI, Kwock R, Solorzano MM, et al. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6- 1/AZT-100) and in pediatric patients with HIV-I infection. J Acquir Immune Defic Syndr 1993; 6: 1287-96
55. Stretcher BN, Pesce AJ, Frame PT, et al. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994; 8: 763-9
56. Stretcher BN, Pesce AJ, Frame PT, et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 1541-7
57. Robbins BL, Rodman J, McDonald C, et al. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994; 38; 115-21
58. Shelton MJ, Morse GD, Portmore A, et al. Zidovudine recovered from peripheral blood mononuclear cells of HIV-infected patients [abstract P80]. International Congress on Drug Therapy in HIV Infection: 1992 Nov 9-12; Glasgow, Scotland. AIDS 1992 Nov; 6 (1 Suppl.): S35
59. Stretcher BN, Pesce AJ, Hurtubise PE, et al. Pharmacokinetics of zidovudine phosphorylation in patients with the human immunodeficiency virus. Ther Drug Monit 1992; 14: 281-5
60. Törnevik Y, Jacobsson B, Britton S, et al. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1991; 7: 751-9
61. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1009-14
62. Seitte P, Narciso P, Tozzi V, et al. Low-dose zidovudine for AIDS. Lancet 1989; I (8647): 1136-7
63. Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323: 1015-21
64. Dournon E, Matheron S, Rozenbaum W, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988; II (8623): 1297-302
65. Hoggard PG, Veal GJ, Wild MJ, et al. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995; 39: 1376-8
66. Peter K, Gambertoglio J. Effect of long-term zidovudine (ZDV) administration on intracellular ZDV phosphorylation in HIV positive patients [ abstract PII-56]. 69th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics: 1995 Mar 15-17; San Diego (CA). Clin Pharmacol Ther 1995; 54: 178
67. Stretcher BN. State-of-the-art of zidovudine monitoring. J Clin Lab Anal 1991; 5: 60-8
68. Stretcher BN, Pesce AJ. Intracellular monitoring of nucleoside analogues: a new frontier. Ann Clin Lab Sci 1991; 21: 340-2
69. Stretcher BN, Pesce AJ, Murray JA, et al. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther Drug Monit 1991; 13: 325-31
70. Stretcher BN, Pesce AJ, Wermeling JR, et al. In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes. Ther Drug Monit 1990; 12: 481-9
71. Mentré F, Escolano S, Diquet B, et al. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol 1993; 45: 397-407
72. Bareggi SR, Cinque P, Mazzei M, et al. Pharmacokinetics of zidovudine in HIV-positive patients with liver disease. J Clin Pharmacol 1994; 34: 782-6
73. Taburet A-M, Naveau S, Zorza G, et al. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Thcr 1990; 47: 731-9
74. Fletcher CV, Rhame FS, Beatty CC, et al. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 1992; 12: 429-34
75. Child S, Montaner J, Tsoukas C, et al. Canadian multicenter azidothymidine trial: AZT pharmacokinetics. J Acquir Immune Defic Syndr 1991; 4: 865-70
76. Singles E, Pioger J-C, Taburet A-M, et al. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 1989; 46: 190-7
77. Burger DM, Meenhorst PL, Mulder JW, et al. Pharmacokinetics of zidovudine and metabolites in a patient with HIV-associated nephropathy and severe renal impairment. Drug Invest 1994; 7: 282-7
78. Burger DM, Meenhorst PL, Koks CW, et al. Drug interactions with zidovudine. AIDS 1993; 7: 445-60
79. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110: 279-85
80. Chiang H, Shelton M, Hewitt R, et al. Relationship between surrogate marker response (SMR) and zidovudine population pharmacokinetics [abstract no. 319, session 32]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 1993 Oct 17-20; New Orleans (LA).
81. Collier AC, Tartaglione T, Corey L. A reduced dose of zidovudine in patients with AIDS. N Engl J Med 1991; 324: 996
82. Drusano GL, Balis FM, Gitterman SR, et al. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother 1994; 38: 1726-31
83. Gøtsche PC, Melander H, Norrby SR, et al. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. (Nordic Medical Research Councils' HIV Therapy Group.) BMJ 1992; 304: 13-7
84. Sale M, Sheiner LB, Volberding P, et al. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993; 54: 556-66
85. Tartaglione TA, Collier AC, Coombs RW, et al. Acquired immunodeficiency syndrome: cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol 1991; 48: 695-9
86. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-9
87. Barry M, Howe JL, Back DJ, et al. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol 1994; 37: 7-12
88. Baxter R, Drew WL, Enos L. Pharmacokinetics and toxicity of zidovudine [abstract no. 18]. 6th AIDS Clinical Trials Group Meeting: 1989 Jul; Bethesda (MD).
89. Gelmon K, Montaner JSG, Fanning M, et al. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 1989; 3: 555-61
90. Grau JM, Masanés F, Pedrol E, et al. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann Neurol 1993; 34: 206-11
91. 9/L or less. Arch Intern Med 1992; 152: 2286-92
92. Scherpbier HJ, Prakken ABJ, De Graeff-Meeder ER, et al. Treatment of 12 HIV-infected children with zidovudine [in Dutch]. Ned Tijdschr Geneeskd 1993; 137: 1610-3
93. Vocks-Hauck M, Wintergerst U, Rolinski B, et al. Side effects of zidovudine in correlation to plasma levels in children [abstract P86]. International Congress on Drug Therapy in HIV Infection: 1992 Nov 9-12; Glasgow, Scotland. AIDS 1992; 6 (1 Suppl.): S37
94. Tartaglione TA, Collier AC, Opheim K, et al. Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Antimicrob Agents Chemother 1991; 35: 2225-31
95. Meng T-C, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med 1992; 116: 13-20
96. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989; 321: 1621-5
97. Coombs RW, Collier AC, Allain J-P, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989; 321: 1626-31
98. Piatak Jr M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-54